[go: up one dir, main page]

PL3215147T3 - Związki norketaminy osłabiającej działanie układu nerwowego i sposoby - Google Patents

Związki norketaminy osłabiającej działanie układu nerwowego i sposoby

Info

Publication number
PL3215147T3
PL3215147T3 PL15856205.8T PL15856205T PL3215147T3 PL 3215147 T3 PL3215147 T3 PL 3215147T3 PL 15856205 T PL15856205 T PL 15856205T PL 3215147 T3 PL3215147 T3 PL 3215147T3
Authority
PL
Poland
Prior art keywords
neuro
methods
attenuating norketamine
compounds
norketamine compounds
Prior art date
Application number
PL15856205.8T
Other languages
English (en)
Inventor
Alex Nivorozhkin
Nelson Landrau
Original Assignee
Acadia Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc. filed Critical Acadia Pharmaceuticals Inc.
Publication of PL3215147T3 publication Critical patent/PL3215147T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001Acyclic or carbocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL15856205.8T 2014-11-04 2015-11-04 Związki norketaminy osłabiającej działanie układu nerwowego i sposoby PL3215147T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462074645P 2014-11-04 2014-11-04
PCT/US2015/059113 WO2016073653A1 (en) 2014-11-04 2015-11-04 Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods

Publications (1)

Publication Number Publication Date
PL3215147T3 true PL3215147T3 (pl) 2024-06-24

Family

ID=55909773

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15856205.8T PL3215147T3 (pl) 2014-11-04 2015-11-04 Związki norketaminy osłabiającej działanie układu nerwowego i sposoby

Country Status (18)

Country Link
US (5) US10252982B2 (pl)
EP (2) EP4393487A3 (pl)
JP (2) JP6882180B2 (pl)
KR (1) KR102604397B1 (pl)
CN (2) CN107106529A (pl)
AU (1) AU2015343083B2 (pl)
CA (1) CA2966737A1 (pl)
DK (1) DK3215147T3 (pl)
ES (1) ES2977383T3 (pl)
FI (1) FI3215147T3 (pl)
HU (1) HUE066468T2 (pl)
LT (1) LT3215147T (pl)
PL (1) PL3215147T3 (pl)
PT (1) PT3215147T (pl)
RS (1) RS65411B1 (pl)
RU (1) RU2771275C2 (pl)
SI (1) SI3215147T1 (pl)
WO (1) WO2016073653A1 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
ES2829279T3 (es) 2014-04-17 2021-05-31 Develco Pharma Schweiz Ag Forma de dosificación oral de ketamina
SI3215147T1 (sl) 2014-11-04 2024-05-31 Acadia Pharmaceuticals Inc. Nevroatenuacijske spojine norketamina in postopki
WO2016186968A1 (en) * 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
WO2017180589A1 (en) * 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
WO2018053221A1 (en) * 2016-09-16 2018-03-22 Biopharma Works, Llc Hydroxynorketamine prodrugs
AU2017351437B2 (en) * 2016-10-27 2022-01-27 National University Corporation Chiba University Application of (S)-norketamine and salt thereof as pharmaceutical
EP3609481A4 (en) 2017-04-13 2021-05-26 Ovid Therapeutics Inc. DEVELOPMENTAL ENCEPHALOPATHY TREATMENT METHODS
EP3641742A2 (en) * 2017-06-23 2020-04-29 Develco Pharma Schweiz AG Hydroxynorketamine for the use in the treatment of depression
CN111201217A (zh) 2017-07-31 2020-05-26 斯玛尔药物有限公司 羟基去甲氯胺酮的晶型
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
WO2020194087A2 (en) 2019-03-25 2020-10-01 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
CA3077645A1 (en) 2017-10-10 2019-04-18 Douglas Pharmaceuticals Ltd. A solid extended-release pharmaceutical formulations comprising ketamine or norketamine
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
PT3505157T (pt) 2017-12-29 2022-02-18 Celon Pharma Sa Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
EP3813808A4 (en) 2018-05-04 2022-01-26 Perception Neuroscience, Inc. Methods of treating substance abuse
US12036189B2 (en) 2018-06-27 2024-07-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
US11865088B2 (en) 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
WO2020075134A1 (en) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN114302721B (zh) * 2019-08-06 2025-07-18 加利福尼亚大学董事会 聚酮的可规模化制备
MX2022004257A (es) 2019-10-11 2022-05-26 Pike Therapeutics Inc Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー. 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder
WO2021137148A1 (en) * 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
AU2021275863A1 (en) * 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
CN114524737B (zh) * 2020-11-23 2024-10-22 江苏恒瑞医药股份有限公司 一种取代的环己酮类化合物
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
EP4329737A1 (en) * 2021-04-30 2024-03-06 Progressive Therapeutics Inc Ketamine and cannabis for the treatment of emotional disorders
CN116730853A (zh) * 2022-03-04 2023-09-12 上海致根医药科技有限公司 新型氨基酮类化合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
JP2006510618A (ja) * 2002-11-18 2006-03-30 ヤウポン セラピューティクス,インコーポレーテッド ノルケタミンおよびケタミン/ノルケタミンプロドラッグの鎮痛的使用
US20100076087A1 (en) * 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
WO2008134525A1 (en) * 2007-04-26 2008-11-06 Auspex Pharmaeuticals, Inc. Deuterium labelled ketamine
WO2009131794A1 (en) 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
EP3960162A1 (en) 2013-08-26 2022-03-02 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
SI3215147T1 (sl) 2014-11-04 2024-05-31 Acadia Pharmaceuticals Inc. Nevroatenuacijske spojine norketamina in postopki

Also Published As

Publication number Publication date
CN115521217A (zh) 2022-12-27
RS65411B1 (sr) 2024-05-31
EP3215147A1 (en) 2017-09-13
RU2771275C2 (ru) 2022-04-29
JP6882180B2 (ja) 2021-06-02
US20190263749A1 (en) 2019-08-29
KR102604397B1 (ko) 2023-11-21
WO2016073653A1 (en) 2016-05-12
RU2017119222A3 (pl) 2019-06-07
US20220402863A1 (en) 2022-12-22
US10981859B2 (en) 2021-04-20
US12466783B2 (en) 2025-11-11
EP3215147A4 (en) 2018-05-30
US20220106258A1 (en) 2022-04-07
EP4393487A3 (en) 2024-08-21
AU2015343083A1 (en) 2017-06-08
ES2977383T3 (es) 2024-08-22
US20170355663A1 (en) 2017-12-14
US20230192593A1 (en) 2023-06-22
US10252982B2 (en) 2019-04-09
HUE066468T2 (hu) 2024-08-28
CA2966737A1 (en) 2016-05-12
LT3215147T (lt) 2024-04-25
AU2015343083B2 (en) 2020-07-23
SI3215147T1 (sl) 2024-05-31
KR20170083575A (ko) 2017-07-18
JP2021120389A (ja) 2021-08-19
US11603348B2 (en) 2023-03-14
EP3215147B1 (en) 2024-02-28
EP4393487A2 (en) 2024-07-03
FI3215147T3 (fi) 2024-04-18
PT3215147T (pt) 2024-04-18
CN107106529A (zh) 2017-08-29
US11613515B2 (en) 2023-03-28
DK3215147T3 (da) 2024-04-02
JP2018501299A (ja) 2018-01-18
RU2017119222A (ru) 2018-12-06

Similar Documents

Publication Publication Date Title
ZA201804070B (en) Eif4-a-inhibiting compounds and methods related thereto
LT3215147T (lt) Neurologinį poveikį mažinantys norketamino junginiai ir būdai
DK3236972T3 (en) Antivirale N4-hydroxycytidin-derivativer
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
AU361515S (en) Dishrack
GB201413086D0 (en) Methods
SG11201704473WA (en) New methods and uses
IL251107A0 (en) Compounds and methods
GB201608779D0 (en) Methods and compounds
GB201608776D0 (en) Methods and compounds
GB201408745D0 (en) Methods
GB201419650D0 (en) Modified heterocyclase
GB201415250D0 (en) Compound and method
GB201408091D0 (en) Methods and uses
DK3145380T3 (en) Toiletventilationssystem
GB201415685D0 (en) Methods
AU5288P (en) FLOMANTOG Mandevilla sanderi
GB201404301D0 (en) Compounds and combinations
GB201416086D0 (en) Methods and uses
GB201416073D0 (en) Methods and uses
GB201414122D0 (en) Methods
GB201407599D0 (en) New compounds and uses
GB201407596D0 (en) New compounds and uses
GB201406991D0 (en) Methods
GB201402467D0 (en) New Compounds and uses